The effect of iron carboxymaltose treatment on quality of life in women with iron deficiency

Demir eksikliği olan kadınlarda demir karboksimaltoz tedavisinin hayat kalitesine etkisi

Çağlar Helvacıoğlu 1, Murat Ekin 2

1 İstanbul Teaching and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey
2 Bakırköy Dr. Sadi Konuk Teaching and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey

Abstract

Aim: Iron deficiency is the most common cause of anemia in over the world and affects 20% of women, even in developed countries. In this study, our aim is to calculate the change in the quality of life of patients treated with parenteral ferric carboxymaltose.

Methods: In this retrospective cohort study, quality of life scores were evaluated before and after 6 weeks of treatment using the Short Form 36 scale. Fifty patients receiving parenteral ferric carboxymaltose treatment in Bakırköy Dr. Sadi Konuk Training and Research Hospital, Department of Gynecology and Obstetrics were included.

Results: Pretreatment ad posttreatment hemoglobin values were 8.22 g/dl and 12.02 g/dl, respectively. Pretreatment physical role functioning score was 34.7 (39) and it was calculated as 54.2 (39.8) after the treatment (P=0.006). There were no significant differences between pre- and post-treatment emotional strength, (P=0.330), energy vitality, (P=0.210), mental health (P=0.910) scores and sub-dimensions. Minor side effects were observed in 3 patients.

Conclusion: Parenteral ferric carboxymaltose therapy significantly improves quality of life, especially physical role strength. Iron deficiency should be replaced effectively.

Keywords: Iron, Anemia, Quality of life, Gynecology
Introduction

When negative iron balance occurs in the body (due to chronic blood loss, increased need for iron, absorption deficiency), hemoglobin (Hb) synthesis is maintained by the mobilization of iron from the stores, and if the iron stores do not provide the iron necessary for Hb synthesis, iron deficiency anemia (IDA) develops [1].

It is known that more than 30% of the patients in developed countries who are admitted to the hospital have anemia and this rate is higher in developing countries [2]. In the world and in Turkey, the most common factor that may cause anemia is iron deficiency. In developed countries, 3% of adult men, 20% of women and 50% of pregnant women have iron deficiency [3,4].

The prevalence of etiologic factors in IDA varies according to age groups. The most prominent factors are type of feeding in 0-2-year-old children, menstrual loss in fertile women and gastrointestinal system disorders in elderly people. Nutritional disorders and parasitic diseases gain importance in the etiology especially in developing countries [5].

The actual control of IDA has two stages: Treatment of the underlying disease and correcting iron deficiency. The aim of treatment is to gradually increase the iron levels and Hb to normal values [6].

The most common treatment method in IDA is oral iron replacement therapy [7]. The main advantage of oral replacement is that it is an inexpensive method. However, it has some disadvantages such as the need for long-term use, adverse effects on gastrointestinal system (GIS) and difficulties in patient compliance. We observed that the oral iron therapy is not used optimally in majority of our patients. Intravenous (IV) iron replacement is a relatively expensive form of treatment, and less patient compliance problems and lack of adverse effects on GIS make it a better treatment option.

Short Form 36 (SF-36) has been developed and presented to use by Rand Corporation to assess the quality of life [8]. SF-36 is a multi-purpose, short health survey form consisting of 36 questions. It has been successfully adapted to general population in many countries, particularly in the United States of America. SF-36 has been translated into Turkish by Bilir Kaya et al. [9] and its reliability and validity have been assessed in patients with rheumatoid arthritis.

The aim of this study was to determine the effects of IV ferric carboxymaltose treatment on quality of life in female patients presenting with anemia symptoms and diagnosed with iron deficiency anemia.

Materials and methods

This retrospective cohort study included 50 women treated with IV ferric carboxymaltose for iron deficiency anemia in Bakirkoy Dr. Sadi Konuk Hospital, Department of Gynecology and Obstetrics. Iron deficiency anemia of the patients was due to gynecological conditions and the patients with chronic kidney disease or gastrointestinal disorders were excluded from the study.

Ferric carboxymaltose (Ferinject®) is a novel nondextran-containing complex of iron that allows for administration of a large replenishment dose (≤1.000 mg of iron) over a short infusion period (15 minutes). Patients those require higher doses were not included in the study.

Ethics committee approval was obtained from the Ethics and Research Committee of Bakirkoy Dr. Sadi Konuk Training and Research Hospital (REF: 2016/04/10). All procedures in this study involving human participants were performed in accordance with the 1964 Helsinki Declaration and its later amendments. After obtaining oral and written informed consent from the patients who accepted to join the study, patients were asked to complete the SF-36 questionnaire before and at 6 weeks after the treatment. Nine patients were excluded from the study as they did not attend follow-ups.

Statistical analysis

Statistical analysis was performed using SPSS 23 package program (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: USA). The normal distribution of the data was evaluated by Shapiro-Wilk test. Mean standard deviation and median values were given for descriptive statistics. T test and Wilcoxon signed-rank tests were used to compare normally and non-normally distributed data, respectively. Cronbach Alpha coefficient was calculated for internal consistency of data set. The lowest reliability level was accepted as 0.50. G*Power 3.1.9.2 was used to calculate the power of the tests.

Results

This study included 41 volunteers who completed the baseline SF-36 questionnaire. The mean age of the patients was 43.8 (4.9) years, mean height was 1.61 (0.5) (cm), mean weight was 71.4 (9.2) kg and body mass index (BMI) was 27.6 (3.5) kg/m² (Table 1).

Before treatment physical role functioning score was 34.7 (39) and after treatment it increased to 54.2 (39.8) (P=0.006). The median value of physical role difficulty was higher after treatment (Table 2) Post-hoc power, which was statistically significant, was 91% for this variable.

Physical functions score was 58.1 (24.3) before and 64.6 (23.1) after treatment (P=0.059). The pre- and posttreatment pain scores were 46.6 (29.8) and 51.7 (23.89), respectively (P=0.33). General health score increased to 40.6 (20.2) from 38.7 (19.6) after treatment (P=0.49) (Table 2). Improvement in these subscales were numerical, but not statistically significant.

Emotional role functions score was 52.4 (43.2) before treatment, decreasing to 45.1 (44.4) after treatment (P=0.33). Energy and vitality scores were 40.2 (18.8) before and 43.7 (19.9) after treatment (P=0.21). Pre- and post-treatment mental health scores were 56.9 (17.3) and 56.6 (20.5), respectively (P=0.91). The treatment did not significantly affect these quality of life subcategories (Table 3).

While the mean hemoglobin level of the participants was 8.29 gr/dl before the treatment, it increased to 12.2 gr/dl at 6th week following treatment (Table 4). According to these data, there was a 3.8 gr/dl difference between pre-treatment and post-treatment hemoglobin levels.

We observed minor side-effects in three participants which were temporary falling of sickness in one patient and...
rashes around the infusion site in two patients. There were no major side-effects requiring hospitalization and additional treatments.

Table 1: Descriptive statistics for the mean age, weight, height, and BMI of the study group

| (n=41) | Mean (SD) |
|--------|-----------|
| Age (years) | 43.8 (23.9) |
| Height (m) | 1.61 (0.05) |
| Weight (Kg) | 71.4 (9.2) |
| BMI | 27.6 (3.5) |

SD: Standard deviation

Table 2: The comparison between the levels of physical functions, physical role difficulty, pain, general health quality of life before and after treatment

| Physical functions | Before treatment Mean (SD) | After treatment Mean (SD) | P-value |
|-------------------|---------------------------|--------------------------|---------|
| Physical role functioning | 52.4 (43.2) | 45.1 (44.4) | 0.330 |
| Energy and vitality | 40.2 (18.8) | 43.7 (19.9) | 0.320 |
| Mental health | 56.9 (17.3) | 56.6 (20.5) | 0.910 |

SD: Standard deviation, Wilcoxon Signed Ranks Test

Table 3: The comparison between the levels of emotional role difficulty, energy, vitality, and mental health quality of life before and after treatment

| Emotional role functioning | Before treatment Mean (SD) | After treatment Mean (SD) | P-value |
|---------------------------|---------------------------|--------------------------|---------|
| Pain | 46.6 (29.8) | 51.7 (23.8) | 0.330 |
| General health | 38.7 (19.6) | 40.6 (20.2) | 0.490 |

SD: Standard deviation, Wilcoxon Signed Ranks Test, Dependent Sample T Test

Table 4: Before and after treatment hemoglobin levels

| Hemoglobin levels (g/dl) | Before treatment Mean (SD) | After treatment Mean (SD) | P-value |
|--------------------------|---------------------------|--------------------------|---------|
| 8.2 (1.4) | 12.0 (2.4) | 0.001 |

SD: Standard deviation, Dependent Sample T Test

Discussion

Iron is a quite crucial element in oxygen transport. It is found in the structure of hemoglobin in the erythrocytes, myoglobin, and skeletal muscles, and plays important roles in oxygen diffusion and oxygen storage. In addition, it functions in oxidative reactions in the mitochondria and respiratory chain [10]. The most common cause of anemia in patients who were admitted to the gynecology outpatient clinic is iron deficiency. Iron deficiency anemia is a major health problem in both developed and developing countries. The most common cause of iron deficiency in adult patients is iron loss. According to a study by Davas et al. [11], 74.1% of pregnant women in Turkey have IDA. It is known that when menstrual losses cannot be met by iron intake in women of reproductive age, iron deficiency anaemia can easily develop [12]. Viethen et al. [13] have shown that parenteral ferric carboxymaltose balances iron levels in the body and improves the quality of life and physical capacity in patients with pulmonary arterial hypertension and IDA. They have reported that the treatment is well tolerated, and they have not observed any major side-effects. In an effective oral iron treatment, the increase in hemoglobin concentration levels should be 2 g/dl in 3-4 weeks [14]. Regular use, good tolerability and low side-effects are prerequisites for an efficient oral iron treatment. We observed that the majority of patients do not regularly adhere to oral iron therapy in our clinic. We showed that the hemoglobin levels have increased from 8.22 g/dl to 12.02 g/dl at 6 weeks after treatment. Khalafallah et al. [15] have reported an increase in hemoglobin levels similar to the results of our study. In the same study, it has been shown that ferric carboxymaltose increases hemoglobin levels in a shorter time compared to oral iron preparations. Unlike oral iron replacement, the most important advantage of parenteral iron therapy is that it does not require long-term patient compliance.

Parenteral iron therapy has the risk of anaphylaxis. Moore et al. [16] have performed a meta-analysis and have shown that the risk of anaphylaxis is quite low in ferric carboxymaltose molecule. Nevertheless, the parenteral carboxymaltose treatment is generally well-tolerated by the patients. We experienced minor side-effects in three participants. We observed that the majority of patients do not regularly adhere to oral iron therapy in our clinic. A limitation of our study was that the transferrin, ferritin, iron and serum iron binding capacity values were not compared. Future long-term studies may benefit from these parameters.

Limitations

The most important limitations of our study were that it was a single-center study and the number of participants was low. In addition, six weeks for assessing the improvements in quality of life can be considered a brief period. Another limitation of our study was that the transferrin, ferritin, iron and serum iron binding capacity values were not compared. Future long-term studies may benefit from these parameters.

Conclusion

IDA is common in patients admitted to gynecology and obstetrics clinics. Iron deficiency must be effectively replaced, and the underlying reasons must be removed. Oral iron treatment requires regular use and patient compliance. Parenteral ferric carboxymaltose treatment improves hemoglobin levels in a brief time. Ferric carboxymaltose treatment positively improves
quality of life in suitable patients and it is a safe preparation in terms of side-effects.

References
1. Frewin R, Henson A, Provan D. Iron deficiency anemia. BMJ. 1997;314:360-3.
2. Beutler E, Lichtman MA, Coller BS. Iron deficiency, ed. Williams E, Hematology fifth edition. Philadelphia 1995:905-911.
3. DeMaeyer E, Adluri-Tegman M. The prevalence of anemia in the world. World Health Stat Q. 1995;38:302-6.
4. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. JAMA. 1997;277:977-9.
5. Alt R. Demir eksikliği anemisi. In Dolar E. İç hastalıkları 1.B.İstanbul: Nobel Tıp Kitabevleri. 2005.s.557-7.
6. Frohder B, Collingswood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth. 2014;14:115.
7. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267-78.
8. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
9. Kaya BB, İşgüçtuğlu A. Reliability and validity of the Turkish version of short form 36 (SF-36) in patients with rheumatoid arthritis. J Surg Med. 2018;2:11-6.
10. Lee RG. Iron deficiency and iron-deficiency anemia Eds: Lee R.G, Bithell C.T, Wintrobe’s clinical Hematology 10th edition.1999. Lea-Febiger. Chapter 34.979-1010.
11. Duvas I, Marangoz D, Yavakan A, Akyol A, Bakirc B. Akılækite dejju kevelikleri anemilerde demir alınımının maternal, doğum ve perinatal sonuçlara etkileri. J Turk Soc Obstet Gynecol. 2008;5:174-81.
12. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med. 1967;37:62-9.
13. Verhein T, Gerhardt F, Dumitrescu D, Knop BS, Freyhaus H, Rudolph TK, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: A pilot study. Int J Cardiol. 2014;175:233-9.
14. Çetin M, Eser B, Güven M, Ünal A, Afanah M. Oral demir tedavisinde ferro sülfat ve ferrik polimaltoz etkinliğinin karşılaştırılması. THOD. 1999;9;96-100.
15. Khalafallah A, Annemarie H, Anthony C, Fayez H, Emi W, Christine K, et al. A prospective randomised controlled trial of a single intravenous infusion of ferric carboxymaltose, versus single intravenous iron polysalt or daily oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy Treatment of Pregnancy Anaemia. Semin Hematol. 2018;55:223-34.
16. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders. 2011;11:4.
17. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: A review of randomized controlled trials across different indications. Arzneimittelforschung. 2010;60:386-98.
18. Breyeuma C, Gilga F, Bejaian C, Strathova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet. 2008;101:67-73.
19. Sanghoon L, Ki-Jin R, Eun SL, Keun HL, Jeong Jl, Tak K. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menstruation: An open-label, multicenter, randomized study. J Obstet Gynecol Res. 2019;45:858-64.

This paper has been checked for language accuracy by JOSAM editors.
The National Library of Medicine (NLM) citation style guide has been used in this paper.